PL9643 (Melody-1)
Dry Eye Disease
Phase 3Active
Key Facts
About Palatin Technologies
Palatin Technologies is pioneering a novel approach to treating inflammatory and autoimmune conditions by harnessing the body's natural melanocortin system to resolve inflammation and promote tissue healing. The company has advanced clinical programs in dry eye disease and uveitis, a strategic collaboration with Boehringer Ingelheim in retinal diseases, and a marketed product, Vyleesi. With a focus on ocular conditions and metabolic disorders, Palatin aims to address significant unmet medical needs where current anti-inflammatory therapies are limited by safety and efficacy concerns.
View full company profile